# Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

> **NCT02550756** · PHASE1 · COMPLETED · sponsor: **Centrexion Therapeutics** · enrollment: 11 (actual)

## Conditions studied

- Morton's Neuroma

## Interventions

- **DRUG:** CTNX-4975

## Key facts

- **NCT ID:** NCT02550756
- **Lead sponsor:** Centrexion Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-11
- **Final completion:** —
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2015-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02550756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02550756, "Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02550756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*